A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models

RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the technology is being leveraged for rapid emergency response. In this report, we assessed immunogenicity and, for the first time, toxicity, biodistribution, and protective efficacy in preclinical models of a two-dose self-am...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruggi, Giulietta, Mallett, Corey P., Westerbeck, Jason W., Chen, Tiffany, Lofano, Giuseppe, Friedrich, Kristian, Qu, Lin, Sun, Jennifer Tong, McAuliffe, Josie, Kanitkar, Amey, Arrildt, Kathryn T., Wang, Kai-Fen, McBee, Ian, McCoy, Deborah, Terry, Rebecca, Rowles, Alison, Abrahim, Maia Araujo, Ringenberg, Michael A., Gains, Malcolm J., Spickler, Catherine, Xie, Xuping, Zou, Jing, Shi, Pei-Yong, Dutt, Taru, Henao-Tamayo, Marcela, Ragan, Izabela, Bowen, Richard A., Johnson, Russell, Nuti, Sandra, Luisi, Kate, Ulmer, Jeffrey B., Steff, Ann-Muriel, Jalah, Rashmi, Bertholet, Sylvie, Stokes, Alan H., Yu, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721936/
https://www.ncbi.nlm.nih.gov/pubmed/34990810
http://dx.doi.org/10.1016/j.ymthe.2022.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721936/
https://www.ncbi.nlm.nih.gov/pubmed/34990810
http://dx.doi.org/10.1016/j.ymthe.2022.01.001

Ejemplares similares